Technology | Cardiac Resynchronization Therapy Devices (CRT) | June 28, 2016

St. Jude Medical Expands Heart Failure Portfolio with SyncAV CRT Technology

Real-time responsive pacing technology provides physicians another option for managing heart failure patients not responsive to other therapies

St. Jude Medical, CE Mark, SyncAV CRT, MultiPoint Pacing, CardioStim 2016

June 28, 2016 — St. Jude Medical Inc. announced CE Mark approval and launch of SyncAV CRT software, designed to build upon the company’s MultiPoint Pacing technology and further optimize its comprehensive cardiac resynchronization therapy (CRT) portfolio.

MultiPoint Pacing technology with the SyncAV CRT software algorithm is designed to address and effectively treat heart failure patients who are not responsive to other pacing options. The SyncAV technology, which automatically adjusts pacing based on real-time changes in a patient’s cardiac condition, also provides physicians the opportunity to further improve treatment of patients who have responded positively to traditional CRT.

In addition to the approval of SyncAV CRT software, the company has also received CE Mark approval for the Quadra Assura MP CRT-Defibrillator (CRT-D) with full-body magnetic resonance (MR) labeling. With the updated labeling, patients will have unrestricted access to MRI diagnostic testing. Approvals of the SyncAV CRT software and Quadra Assura MP CRT-D with full-body MRI support the continued rollout of MultiPoint Pacing technology throughout Europe.

“Although we have made substantial improvements in how we treat heart failure patients, there are still certain patients who are not getting the outcomes with traditional CRT that we would like to see. The SyncAV CRT algorithm dynamically individualizes programming to work towards providing patients with the right settings at the right time helping offer the best possible outcome for even our most complex patients,” said Timothy Betts, M.D., consultant cardiologist and electrophysiologist at the Oxford Heart Centre in the John Radcliffe Hospital. “Our goal is to utilize the technology to improve outcomes while offering patients who do not respond to therapy with additional options for treatment.”

For patients suffering from heart failure, CRT technology resynchronizes the lower chambers (ventricles) of the heart by sending uniquely programmed electrical impulses to stimulate each ventricle to beat in sync to offer the best cardiac performance.

The MultiPoint Pacing technology, featured on the Quadra Assura MP CRT-D and the Quadra Allure MP CRT-P, including SyncAV CRT technology, as well as the Quadra Assura MP CRT-D with full-body MRI were all showcased at the CardioStim-EHRA Europace 2016 annual conference. In addition, the investigational device exemption (IDE) clinical study results for the MultiPoint Pacing technology were presented during a late-breaking clinical trial session at the congress. The MPP IDE study met its primary endpoints of safety and efficacy, and additional analyses indicated a positive impact of MultiPoint Pacing programming on patient response to therapy.

An Italian registry on multipoint left-ventricular pacing in CRT (IRON-MPP) was presented at the congress and also published in Europace. Author and presenter of the data, Giovanni Forleo, M.D., electrophysiologist at the University Hospital of Tor Vergata, Rome, Italy, said, “Our goal with this study was to help build a large body of clinical evidence to inform clinical decision-making standards for the management of heart failure patients implanted with MultiPoint Pacing capable CRT-D devices. The results of this study show that establishing optimal programming with the MultiPoint Pacing technology can realize a maximized benefit for patients.”

CRT includes a lead (Quartet Quadripolar LV Lead) placed on the left ventricle. The left ventricle pumps oxygenated blood from the heart out to the rest of the body. MultiPoint Pacing technology is designed to deliver independent electrical pulses to multiple locations on the Quartet lead to make the heart’s lower chambers pump in a more coordinated way to mirror the natural contractions of a healthy heart.

The St. Jude Medical MORE CRT MPP clinical study is designed to demonstrate the benefits of the St. Jude Medical MultiPoint Pacing technology in improving patient response to CRT therapy.

For more information: www.sjm.com

Related Content

Surgery Could Reduce Frailty in Adults With Heart Failure
News | Heart Failure| November 17, 2017
November 17, 2017 — Common practice, and recently published research, shows that the risk of complications with surge
News | Heart Failure| November 13, 2017
November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and
Mexican Doctors Safely Reuse Donated Pacemakers After Sterilization
News | Pacemakers| November 10, 2017
Mexican doctors have safely reused donated pacemakers after sterilization, shows a study presented at the 30th Mexican...
Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.

 

 

Feature | Atrial Fibrillation| November 07, 2017
November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technolog
The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was in October 2017.

The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was the No. 1 most popular article on DAIC in October.

Feature | November 03, 2017 | Dave Fornell
November 3, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Card
Societies Detail Treatment for Patients With Ventricular Arrhythmias
News | EP Lab| October 30, 2017
The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published...
Scientists Reverse Advanced Heart Failure in Mouse Model
News | Heart Failure| October 30, 2017
October 30, 2017 — Researchers have discovered a previously unrecognized healing capacity of the heart.
CorInnova Awarded Seminal Patent for Minimally Invasively-Delivered Soft Robotic Heart Device
News | Artificial Heart| October 27, 2017
CorInnova Inc. announced it has received notice of allowance of a seminal patent to protect its intellectual property...
Videos | EP Mapping and Imaging Systems| October 24, 2017
This video, provided by Acutus Medical, demonstrates a patient case showing the use of the AcQMap high-resolution ele
Acutus Medical Receives FDA Clearance for AcQMap Cardiac Mapping Technology
Technology | EP Mapping and Imaging Systems| October 24, 2017
Acutus Medical announced that the U.S. Food and Drug Administration (FDA) has cleared the AcQMap High Resolution...
Overlay Init